Eyelash preservation during chemotherapy and topical prostaglandin therapy.
Moroi
Sayoko E
SE
D000577:Amides / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D000069580:Bimatoprost; D001943:Breast Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D003008:Cloprostenol / Q000031:analogs & derivatives / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005140:Eyelashes / Q000187:drug effects* / Q000254:growth & development*; D005260:Female; D005902:Glaucoma, Open-Angle / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D000077338:Latanoprost; D008875:Middle Aged; D009798:Ocular Hypertension; D009883:Ophthalmic Solutions; D011453:Prostaglandins / Q000008:administration & dosage / Q000627:therapeutic use*; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use; D000069557:Travoprost; D016896:Treatment Outcome
D000577:Amides; D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011453:Prostaglandins; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D004317:Doxorubicin; D003520:Cyclophosphamide; D000069580:Bimatoprost; D000069557:Travoprost